Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly
Authors' conclusion
Cancer risk is increased in acromegaly, but not in CNFPA patients. Cumulative exposure to IGF-1 excess is a predictor of cancer in acromegaly. Our data suggest that cancer risk in acromegaly relates to the degree and duration of IGF-1 excess and that full appreciation of this risk requires long-term follow up.
Study context
- Population
- Patients with acromegaly and patients with clinically nonfunctioning pituitary adenoma (CNFPA) from the same underlying New York City population
- Participants
- 598 vs 292
- Exposure
- Acromegaly vs CNFPA cohorts; cumulative IGF-1 excess as cancer predictor
- Acromegalyn = 598
- CNFPAn = 292reference
- Outcome
- Cancer, with cumulative exposure to IGF-1 excess tested as predictor
- Follow-up
- Long-term
Methodological detailscomparison with Surveillance, Epidemiology, and End Results (SEER) data
- Comparison with SEER data
Main finding
As reported in the abstract
Predictors of cancer
Cumulative exposure to IGF-1 excess, OR (P = .01)
1.278
1.060–1.541
Years from acromegaly diagnosis to cancer or last follow-up, OR (P = .024)
1.03
1.004–1.057
Age at follow-up, OR (P < .001)
1.064
1.047–1.082
Observational data: associations, not effects.
Further findings
| Outcome | Acromegaly | CNFPA | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Cancer prevalence · last follow-up | 22.6% | 12.7% | 1.99 (1.34–2.97) | P = 0.0005 | |
| 0.20.5125Odds ratio (log scale) |
| Outcome | Acromegaly | CNFPA |
|---|---|---|
| Overall standardized incidence ratio for cancer vs SEER | 1.78 (CI 1.51–1.81) | 1.26 (CI 0.89–1.70) |
Original publication
Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly. J Clin Endocrinol Metab. Published 10 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →